Drug Discovery and Development

Enzo launches RNA gene expression platform for HPV

The platform's products combine sequence-specific probes with Enzo's LoopRNA in situ hybridization (ISH) technology, enabling the products to detect target genes in tissue or cell samples while preserving the morphology, Enzo said. This study of single cells within their native tissue environment, called spatial biology, helps scientists characterize and understand disease, Enzo added.

September 25, 2022

Lunaphore, Nucleai to provide AI-based spatial biology analysis

Combining Lunaphore's Comet hyperplex staining and imaging platform, a fully automated sequential immunofluorescence (seqIF) instrument, with Nucleai's Atom artificial-intelligence (AI) spatial biology platform will enable the companies to generate new insights from tissue biopsies and provide labs with an integrated end-to-end spatial biology workflow.

September 8, 2022

BD, Labcorp to develop flow cytometry CDx

Specifically, the agreement creates a framework for BD and Labcorp Drug Development to collaborate on flow cytometry-based CDx opportunities with pharmaceutical partners.

August 8, 2022

Nucleai, Ultivue to partner on AI-based drug development platform

Under a comarketing agreement, the firms will integrate Nucleai's AI spatial models with Ultivue's imaging technology with the aim of speeding drug development.

June 5, 2022

Stilla and Promega sign comarketing agreement

The companies have combined Promega's Maxwell liquid biopsy system and Stilla's naica system, a six-color multiplexing digital PCR platform. The pairing enables an optimized workflow for a wide range of applications, including liquid biopsy, sentinel pathogen testing, infectious disease assays, overall cancer research, and drug discovery, according to the vendors.

April 7, 2022

PathAI, GSK partner to accelerate research, drug development

Under the agreement, GSK will gain access to PathAI's technologies in digital pathology, including its artificial intelligence-based measurement of NASH (AIM-NASH) tool, which provides AI-based NASH scoring.

April 4, 2022

Most Popular

Quest launches long-COVID testing panels for consumers

Ohio, Kentucky doctors convicted in scheme to bill Medicaid for millions of dollars in unnecessary urinalysis testing

RNA-seq analysis links protein to spread of pancreatic cancer, reveals potential drug target

Point-of-care test developer Proxim Diagnostics obtains strategic investment from BioMérieux

Patients prefer immediate test results, even when the news is bad

Quest Diagnostics offers suite of services for transplant patients and living donors

AbbVie, Scripps Research to collaborate on COVID-19 treatments

The initial research program was conducted at Calibr, Scripps Research's drug discovery and development division, and received funding from the Bill & Melinda Gates Foundation.

March 14, 2022

Precision Medicine Institute to host show on AI and diagnostics

Attendees will see how AI developed by biotech companies are used in daily applications that support patient care, as well as drug discovery, targeting, and screening. The event will showcase the latest developments and trends in AI.

January 24, 2022

C2N Diagnostics debuts blood test to ID Alzheimer's disease

Samples from PrecivityAD are sent to the company's lab in St. Louis. Development of the test was supported by $2.8 million in funding from the Alzheimer's Drug Discovery Foundation over the past decade.

October 29, 2020

Scipher, Galapagos partner to develop IBD treatments

The two companies will jointly validate multiple IBD targets discovered by Scipher. The partnership will leverage the precision medicine firm's proprietary, artificial intelligence (AI)-driven Network Medicine Platform and molecular patient data.

August 12, 2020

Illumina Accelerator announces new genomics startups

Of the seven companies, three will mark the inaugural funding cycle of Illumina Accelerator Cambridge, U.K., while four other firms will join as part of the eleventh funding cycle in the San Francisco Bay Area, according to Illumina.

June 22, 2020

Twist Bioscience, Sophia Genetics partner on NGS, DNA analysis

South San Francisco, CA-based Twist has developed a DNA synthesis platform that involves manufacturing synthetic DNA for use in NGS preparation and the development of antibody libraries that inform drug discovery. Sophia Genetics, which has offices in the U.S., Switzerland, and France, has developed an AI-powered platform for DNA analysis.

February 25, 2020

Page 1 of 2

Next Page